Neurocrine Biosciences | NBIX - Stock


Neurocrine Biosciences reported $69.3M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
AbbVie USD 4.94B 22M Sep/2025
Acadia Pharmaceuticals USD 29.1M 2.97M Sep/2025
Agios Pharmaceuticals USD 32.03M 1.19M Sep/2025
ALKERMES USD 191M 927K Sep/2025
Alnylam Pharmaceuticals USD 75.38M 3.7M Sep/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.21B 64.9M Sep/2025
BioMarin Pharmaceutical USD 1.38B 42M Sep/2025
Cytokinetics USD 0 0 Dec/2023
Dynavax Technologies USD 73.29M 2.4M Sep/2025
Exelixis USD 27.4M 3.92M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Halozyme Therapeutics USD 185.8M 4.29M Sep/2025
Incyte USD 83.45M 24K Sep/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Neurocrine Biosciences USD 69.3M 12.4M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Repligen USD 160.32M 4.46M Sep/2025
Sarepta Therapeutics USD 1.08B 83.13M Sep/2025
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.63B 127.5M Sep/2025